MediciNova to Participate in Two Investor Conferences in September

MediciNova outlines September investor conference participation while highlighting upcoming Phase 2 and COMBAT-ALS topline data and current cash balance.

Rhea-AI Summary

MediciNova (MNOV) will participate in two investor conferences in September 2026, featuring management presentations and investor meetings in New York.

Executives will join the H.C. Wainwright 28th Annual Global Investment Conference on September 14–16, with a virtual presentation available on demand from September 11 at 7:00 a.m. Eastern time, and the ROTH Capital 5th Annual Healthcare Opportunities Conference on September 29, including a neuroscience panel at 10:00 a.m. Eastern time. The company expects topline data from its Phase 2 MN-001-NATG-202 metabolic disease study by end of Q3 2026 and from the double-blind phase of the COMBAT-ALS study of MN-166 by year-end, and reports a cash position of $25.4 million as of Q2 2026.

Positive

• Topline Phase 2 MN-001-NATG-202 data expected by end of Q3 2026
• COMBAT-ALS MN-166 double-blind topline readout expected by year-end 2026
• Cash position of $25.4 million as of Q2 2026

Negative

• None.

Key Figures

MN-001 topline data: By end of Q3 COMBAT-ALS topline readout: By year-end Cash position: $25.4 million

MN-001 topline data

By end of Q3

Phase 2 MN-001-NATG-202 study in metabolic disease

COMBAT-ALS topline readout

By year-end

Double-blind phase of the MN-166 COMBAT-ALS study

Cash position

$25.4 million

As of Q2 2026

Key Terms

phase 2, topline data, double-blind

3 terms

phase 2 medical

"our Phase 2 MN-001-NATG-202 study in metabolic disease"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

topline data medical

"We expect to report topline data from our Phase 2"

Topline data are the initial, high-level results from a clinical study that show whether the main goals of the trial were met, much like the headline of a news story that summarizes the most important point. Investors care because these early outcomes quickly indicate a drug’s commercial potential and regulatory path — positive topline results can boost a company’s value, while disappointing ones can sharply reduce expected future revenue.

double-blind medical

"the double-blind phase of our lead program"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will participate in two investor conferences during September.

• H.C. Wainwright 28^th Annual Global Investment Conference, September 14-16 at the Lotte New York Palace Hotel. Management will hold one-on-one meetings with investors during the conference. A virtual presentation will be available on demand here starting Friday, September 11^th at 7:00 a.m. Eastern time.
• ROTH Capital 5^th Annual Healthcare Opportunities Conference, September 29 at The Metropolitan Club in New York City. Management will participate in a panel titled “Frontiers in Neuroscience” at 10:00 a.m. Eastern time. In addition, management will hold one-on-one and small group meetings with investors.

Dr. Iwaki comments, “These conferences underscore our commitment to regular interaction and communication with all stakeholders connected to our progress. We continue to work diligently toward an announcement around our key milestones. We expect to report topline data from our Phase 2 MN-001-NATG-202 study in metabolic disease by end of Q3, followed by a topline readout from the double-blind phase of our lead program, the COMBAT-ALS study of MN-166 by year-end. In the meantime, we continue to carefully manage our $25.4 million cash position as of Q2 2026 to ensure sufficient capital to execute on our business and demonstrate optimal shareholder value. We look forward to speaking with investors at each of these conferences, and at subsequent opportunities.”

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has numerous programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT:

David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com

FAQ

Which investor conferences will MediciNova attend and when?

MediciNova will attend the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026, at the Lotte New York Palace Hotel, and the ROTH Capital 5th Annual Healthcare Opportunities Conference on September 29, 2026, at The Metropolitan Club in New York City.

How can investors access MediciNova’s H.C. Wainwright conference presentation?

A virtual presentation will be available on demand starting Friday, September 11, 2026, at 7:00 a.m. Eastern time. Management will also hold one-on-one meetings with investors during the conference.

What will MediciNova’s management do at the ROTH Capital conference?

Management will participate in a panel titled “Frontiers in Neuroscience” at 10:00 a.m. Eastern time on September 29, 2026, and will hold one-on-one and small group meetings with investors.

What upcoming clinical milestones did MediciNova highlight?

The company expects to report topline data from the Phase 2 MN-001-NATG-202 study in metabolic disease by the end of Q3 2026, followed by a topline readout from the double-blind phase of the COMBAT-ALS study of MN-166 by year-end 2026.

What cash position did MediciNova report?

MediciNova reported a cash position of $25.4 million as of Q2 2026 and stated that it continues to carefully manage this balance to ensure sufficient capital to execute on its business.